Skip to main content
SpringerLink
Log in
Book cover

Transforming Growth Factor-β in Cancer Therapy, Volume I pp 333–353Cite as

Mullerian Inhibiting Substance: A Potential Nontoxic, Naturally Occurring Therapeutic Agent for Certain Human Cancers

  • Chapter

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

A considerable body of in vitro and animal in vivo data support our hypothesis that Mullerian Inhibiting Substance (MIS), a biological response modifier of the transforming growth factor-β (TGF-β) superfamily of genes, could be an effective, potentially nontoxic treatment for tumors of Mullerian origin and others expressing the MIS type II receptor (MISRII). Epithelial ovarian cancer will be the first targeted disease because this cancer affects approx 25,000 North American women each year and the high five-year mortality of over 70% results in over 16,000 deaths every year. Preclinical growth inhibition data suggest other much more frequent cancers such as cervical. endometrial, breast, and prostate cancers may be MIS targets as well.

The molecular tools to identify MIS receptor expressing tumors and, therefore, the ability to select patients for treatment are in place. An MIS enzyme-linked immunosorbent assay (ELISA) exists to follow administered doses of MIS, as well. Clinical trials await the production of sufficient supplies of recombinant human MIS for this purpose.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Donahoe PK, Clarke T, Teixeira J, Maheswaran S, MacLaughlin DT. Enhanced purification and production of Mullerian inhibiting substance for diagnostic therapeutic applications. Mol Cell Endo 2003;211:37–41.

    Article  CAS  Google Scholar 

  2. Teixeira J, Maheswaran S, Donahoe PK. Mullerian inhibiting substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Application. Endocr Rev 2001;22:657–674.

    Article  CAS  PubMed  Google Scholar 

  3. DiClemente N, Josso N, Gouedard L, Belville C. Components of the anti-Mullerian hormone signaling pathway in gonads. Mol Cell Endocrinol 2003;211:9–14. Review.

    Article  CAS  Google Scholar 

  4. Josso N, diClemente N. Transduction pathway of anti-Mullerian hormone, a sex-specific member of the TGF-beta family. Trends Endocrinol Metab 2003;14:91–97. Review.

    Article  CAS  PubMed  Google Scholar 

  5. Hudson PL, Dougas I, Donahoe PK. et al. An immunoassay to detect human Müllerian inhibiting substance in males and females during normal development. J Clin Endo Metab 1990;70:16–22.

    Article  CAS  Google Scholar 

  6. Josso N, Legeai L, Forest MG, Chaussain JL, Brauner R. An enzyme linked immunoassay for anti-Mullerian hormone: a new tool for the evaluation of testicular function in infants and children. J Clin Endo Metab 1990;70:23–27.

    Article  CAS  Google Scholar 

  7. Baker ML, Metcalfe SA, Hutson JM. Serum levels of Mullerian inhibiting in boys from birth to 18, as determined by enzyme immunoassay. J Clin Endo Metab 1990;70:11–15.

    Article  CAS  Google Scholar 

  8. Hoshiya M, Christian B, Cromie W, Zhan Y, MacLaughlin DT, Donahoe PK. Persistent Mullerian duct syndrome with a deletion and a novel splicing Mutation in the MIS type II receptor. Birth Def Res 2003;67:868–874.

    Article  CAS  Google Scholar 

  9. Imbeaud S, Faure E, Lamarre I. et al. Insensitivity to anti-mullerian hormone due to a mutation in the human anti-mullerian hormone receptor. Nat Genet 1995;11:382–388.

    Article  CAS  PubMed  Google Scholar 

  10. Belville C, Van Vlijmen H, Ehrenfels C, et al. Mutations of the anti-Müllerian hormone gene in patients with persistent Müllerian duct syndrome: biosynthesis, secretion and processing of the abnormal proteins and analysis using a three-dimensional model. Mol Endocrinol 2004;18:708–721.

    Article  CAS  PubMed  Google Scholar 

  11. Josso N, Belville C, di Clemente N, Picard JY. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum Reprod Update 2005;11:351–356. Review.

    Article  CAS  PubMed  Google Scholar 

  12. Scully RE. Recent progress in ovarian cancer. 1970 Hum Pathol 1970;1:73–98.

    Article  CAS  Google Scholar 

  13. Goodfellow PN, Lovell-Badge R. SRY and sex determination in mammals. Annu Rev Genet 1993: 27:71–92.

    Article  CAS  PubMed  Google Scholar 

  14. Jost A. Recherches sue la differentiation sexulle de l’embryonde lapen. Arch Anat Microsc Morphol Exp 1947;8:379–418.

    Google Scholar 

  15. Jost A. Problems of Fetal Endocrinology: the gonadal and hypophyseal hormones. Res Prog Horm Res 1953;8:379–418.

    Google Scholar 

  16. Price JM, Donahoe PK, Ito Y, Hendren WH, III. Programmed cell death in the Müllerian duct induced by Müllerian inhibiting substance. Am J Anat 1977;149:353–375.

    Article  CAS  PubMed  Google Scholar 

  17. Price JM, Donahoe PK, Ito Y. Involution of the female Müllerian duct of the fetal rat in the organculture assay for the detection of Müllerian inhibiting substance. Am J Anat 1979;156:265–284.

    Article  CAS  PubMed  Google Scholar 

  18. Trelstad RL, Hayashi A, Hayashi K, Donahoe PK. The epithelial-mesenchymal interface of the male Müllerian duct: loss of basement membrane integrity and ductal regression. Dev Biol 1982;92:27–40.

    Article  CAS  PubMed  Google Scholar 

  19. Hayashi A, Donahoe PK, Budzik GP, Trelstad RL. Periductal and matrix glycosaminoglycans in rat Müllerian duct development and regression. Dev Biol 1982;92:16–26.

    Article  CAS  PubMed  Google Scholar 

  20. Ikawa H, Trelstad RL, Hutson JM, Manganaro TF, Donahoe PK. Changing patterns of fibronectin, laminin, type IV collagen, and a basement membrane proteoglycan during rat Müllerian duct regression. Dev Biol 1984;102:260–263.

    Article  CAS  PubMed  Google Scholar 

  21. Dyche WJ. A comparative study of the differentiation and involution of the Müllerian duct and Wolffian duct in the male and female fetal mouse. J Morphol 1979;162:175–209.

    Article  CAS  PubMed  Google Scholar 

  22. Picon R. Action du testicule foetal sur le développement in vitro des canaux de Müller chez le rat. Arch Anat Microsc Morph Exp 1969;58:1–19.

    CAS  Google Scholar 

  23. Donahoe PK, Ito Y, Marfatia S, Hendren WH, III. The production of Mullerian inhibiting substance by the fetal, neonatal and adult rat. Biol Reprod 1976;15:329–334.

    Article  CAS  PubMed  Google Scholar 

  24. Josso N. In vitro synthesis of Mullerian inhibiting hormone by seminiferous tubules isolated from the calf fetal testis. Endocrinology 1973;93:829–834.

    Article  CAS  PubMed  Google Scholar 

  25. Blanchard MG, Josso N. Source of the anti-Müllerian hormone synthesized by the fetal testis: Müllerian-inhibiting activity of fetal bovine Sertoli cells in tissue culture. Pediatr Res 1974;8:968–971.

    Article  CAS  PubMed  Google Scholar 

  26. Picon R. Action of the fetal testis on the development in vitro of the Mullerian ducts in the rat. Arch Anat Microsc Morphol 1969;Exp58:1–19.

    Google Scholar 

  27. Josso N, Forest MG, Picard JY. Müllerian inhibiting activity of calf fetal testis: relationship to testosterone and protein synthesis. Biol Reprod 1975;13:163–167.

    Article  CAS  PubMed  Google Scholar 

  28. Donahoe PK, Ito Y, Price JM, Hendren WH. Müllerian inhibiting substance activity in bovine fetal, newborn, and prepubertal testes. Biol Reprod 1977;16:238–243.

    Article  CAS  PubMed  Google Scholar 

  29. Josso N. Permeability of membranes to the Müllerian inhibiting substance synthesized by the human fetal testis. J Clin Endocrinol Metab 1972;34:265–270.

    Article  CAS  PubMed  Google Scholar 

  30. Donahoe PK, Ito Y, Morikawa Y, Hendren WH, III. Müllerian inhibiting substance in human testes after birth. J Pediatr Surg 1977;12:323–330.

    Article  CAS  PubMed  Google Scholar 

  31. Shen WH, Moore CCD, Ikeda Y, Parker KL, Ingraham HA. Nuclear receptor steroidogenic factor 1 regulates the mullerian inhibiting substance gene: A link to the sex determination cascade. Cell 1994; 77:651–661.

    Article  PubMed  Google Scholar 

  32. Giuili G, Shen WH, Ingraham HA. The nuclear receptor SF-1 mediates sexually dimorphic expression of Mullerian inhibiting substance, in vivo. Development 1997;124:1799–1807.

    CAS  PubMed  Google Scholar 

  33. Arango NA, Lovell-Badge R, Behringer RR. Targeted mutagenesis of the endogenous mouse Mis gene promoter: In vivo definition of genetic pathways of vertebrate sexual development. Cell 1999; 99:409–419.

    Article  CAS  PubMed  Google Scholar 

  34. Hossain A, Saunders GF. Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the mullerian-inhibiting substance promoter. Biol Reprod 2003;69:1808–1814.

    Article  CAS  PubMed  Google Scholar 

  35. Nachtigal MW, Hirokawa Y, EnyeartVan Houten DL, Flanagan JN, Hammer GD, Ingraham HA. Wilms’ tumor 1 and DAX-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998;93:445–454.

    Article  CAS  PubMed  Google Scholar 

  36. Tremblay JJ, Viger RS. Nuclear receptor Dax-1 represses the transcriptional cooperation between GATA-4 and SF-1 in Sertoli cells. Biol Reprod 2001;64:1191–1199.

    Article  CAS  PubMed  Google Scholar 

  37. Lasala C, Carre-Eusebe Picard JY Rey R. Subcellular and molecular mechanisms regulating anti-Mullerian hormone gene expression in mammalian and nonmammalian species. DNA Cell Biol 2004;23:572–585. Review.

    CAS  PubMed  Google Scholar 

  38. Teixeira J, Fynn-Thompson E, Payne A, Donahoe PK. Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level. Endocrinology 1999;140:4732–4738.

    Article  CAS  PubMed  Google Scholar 

  39. Laurich VM, Trbovich AM, O’Neill FH, et al. Müllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome P450 17alpha-hydroxylase/C17-20 lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation. Endocrinology 2002;143:3351–3360.

    Article  CAS  PubMed  Google Scholar 

  40. Sriraman V, Niu E, Matias JR, et al. Müllerian inhibiting substance inhibits testosterone synthesis in adult rats. J Androl 2001;22:750–758.

    CAS  PubMed  Google Scholar 

  41. Bezard J, Vigier B, Tran D, Mauleon P, Josso N. Immunocytochemical study of anti-Mullerian hormone in sheep ovarian follicles during fetal and post-natal development. J Reprod Fertil 1987;80:509–516.

    CAS  PubMed  Google Scholar 

  42. Munsterberg A, Lovell-Badge R. Expression of the mouse anti-Müllerian hormone gene suggests a role in both male and female sexual differentiation. Development 1991;113:613–624.

    CAS  PubMed  Google Scholar 

  43. Ueno S, Manganaro TF, Donahoe PK. Human recombinant Müllerian inhibiting substance inhibition of rat oocyte meiosís is reversed by epidermal growth factor in vitro. Endocrinology 1988;123: 1652–1659.

    Article  CAS  PubMed  Google Scholar 

  44. Kim JH, Seibel MM, MacLaughlin DT, et al. The inhibitory effects of Müllerian inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosaluteal cells. J Clin Endo Metab 1992;75:911–917.

    Article  CAS  Google Scholar 

  45. Durlinger AL, Kramer P, Karel B, et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999;140:5789–5796.

    Article  CAS  PubMed  Google Scholar 

  46. Seifer DB, MacLaughlin DT, Penzias AS, et al. Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid Mullerian inhibiting substance and androgen content. J Clin Endo Metab 1993;76:711–714.

    Article  CAS  Google Scholar 

  47. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum Mullerian inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468–471.

    Article  PubMed  Google Scholar 

  48. Trbovich AM, Sluss PM, Laurich VM, et al. Mullerian inhibiting substance lowers testosterone in luteinizing hormone-stimulated rodents. Proc Natl Acad Sci USA 2001;98:3393–3397.

    Article  CAS  PubMed  Google Scholar 

  49. Lee MM, Seah CC, Masiakos PT, et al. Mullerian inhibiting substance type II receptor expression and function in purified rat Leydig cells. Endocrinology 1999;140:2819–2827.

    Article  CAS  PubMed  Google Scholar 

  50. Baarends WM, Hoogerbrugge JW, Post M, et al. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat. Endocrinology 1995;136:5614–5622.

    Article  CAS  PubMed  Google Scholar 

  51. Bedecarrats GY, O’Neill FH, Norwitz ER, Kaiser UB, Teixeira J. Regulation of gonadotropin gene expression by Mullerian inhibiting substance. Proc Natl Acad Sci USA 2003;100:9348–9353.

    Article  CAS  PubMed  Google Scholar 

  52. Wang PY, Koishi K, McGeachie AB, et al. Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci USA 2005;102:16,421–16,425.

    Article  CAS  PubMed  Google Scholar 

  53. Segev DL, Hoshiya Y, Hoshiya M, et al. Mullerian inhibiting substance regulates NF-κB signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci USA 2002;99:239–244.

    Article  CAS  PubMed  Google Scholar 

  54. Hoshiya Y, Gupta V, Segev DL, et al. Mullerian substance induces NFκB signaling in breast and prostate cancer cells. Mol Cell Endocrinol 2003;211:43–49.

    Article  CAS  PubMed  Google Scholar 

  55. Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, Donahoe PK, Maheswaran S. Müllerian inhibiting substance regulates NFκB signaling and growth of mammary epithelial cells in vivo. J Biol Chem 2001;276:26,799–26,806.

    Article  CAS  PubMed  Google Scholar 

  56. Hoshiya Y, Gupta V, Kawakubo H, et al. MIS Promotes INF-γ-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 2003;278:51,703–51,712.

    Article  CAS  PubMed  Google Scholar 

  57. Picard JY, Josso N. Anti-Mullerian hormone: estimation of molecular weight by gel filtration. Biomedicine 1976;25:147–150.

    CAS  PubMed  Google Scholar 

  58. Picard JY, Josso N. Purification of testicular anti-Mullerian hormone allowing direct visualization of the pure glycoprotein and determination of yield and purification factor. Mol Cell Endocrinol 1984; 34:23–119.

    Article  CAS  PubMed  Google Scholar 

  59. Swann DA, Donahoe PK, Ito Y, Morikawa Y, Hendren WH. Extraction of Müllerian inhibiting substance from newborn calf testis. Dev Biol 1979;69:73–84.

    Article  CAS  PubMed  Google Scholar 

  60. Budzik GP, Swann DA, Hayashi A, Donahoe PK. Enhanced purification of Müllerian inhibiting substance by lectin affinity chromatography. Cell 1980;21:909–915.

    Article  CAS  PubMed  Google Scholar 

  61. Budzik GP, Powell SM, Kamagata S, Donahoe PK. Mullerian inhibiting substance fractionation by dye affinity chromatography. Cell 1983;34:307–314.

    Article  CAS  PubMed  Google Scholar 

  62. Cate RL, Mattaliano RJ, Hession C, et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45:685–698.

    Article  CAS  PubMed  Google Scholar 

  63. Picard JY, Benarous R, Guerrier D, Josso N, Kahn A. Cloning and expression of cDNA for anti-Mullerian hormone. Proc Natl Acad Sci USA 1986;83:5464–5468.

    Article  CAS  PubMed  Google Scholar 

  64. Josso N, Forest MG, Picard JY. Müllerian inhibiting activity of calf fetal testis: relationship to testosterone and protein synthesis. Biol Reprod 1975;13:163–167.

    Article  CAS  PubMed  Google Scholar 

  65. Vigier B, Picard JY, Josso N. A monoclonal antibody against bovine anti-Müllerian hormone. Endocrinology 1982;110:131–137.

    Article  CAS  PubMed  Google Scholar 

  66. Shima H, Donahoe PK, Budzik GP, Kamagata S, Hudson P, Mudgett-Hunter M. Production of monoclonal antibodies for affinity purification of bovine Müllerian inhibiting substance activity. Hybridoma 1984;3:201–214.

    Article  CAS  PubMed  Google Scholar 

  67. Cohen-Haguenauer O, Pcard JY, Mattei MG, et al. Mapping of the gene for antimullerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 1987;44:2–6.

    Article  CAS  PubMed  Google Scholar 

  68. Pepinsky RB, Sinclair LK, Chow EP, et al. Proteolytic processing of Müllerian inhibiting substance produces a transforming growth factor-á-like fragment. J Biol Chem 1988;263:18,961–18,965.

    CAS  PubMed  Google Scholar 

  69. Nachtigal MW, Ingraham HA. Bioactivation of Mullerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc Natl Acad Sci USA 1996;93:7711–7716.

    Article  CAS  PubMed  Google Scholar 

  70. MacLaughlin DT, Hudson PL, Graciano AL, et al. Müllerian duct regression and antiproliferative bioactivities of Müllerian inhibiting substance reside in its carboxy-terminal domain. Endocrinology 1992; 131:291–296.

    Article  CAS  PubMed  Google Scholar 

  71. Wilson CA, di Clemente N, Ehrenfels C, et al. Müllerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-β superfamily. Mol Endocrinol 1993;7:247–257.

    Article  CAS  PubMed  Google Scholar 

  72. Ragin RC, Donahoe PK, Kenneally MK, Ahmad M, MacLaughlin DT. Human Müllerian inhibiting substance: Enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expres Purification 1992;3:236–245.

    Article  CAS  Google Scholar 

  73. Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT. New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromato B 2002;766:89–98.

    Article  CAS  Google Scholar 

  74. Hoshiya Y, Gupta V, Kawakubo H, et al. MIS Promotes INF-γ-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 2003;278:51,703–51,712.

    Article  CAS  PubMed  Google Scholar 

  75. Baarends WM, van Helmond JM, Post M, et al. A Novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Mullerian duct. Development 1994;120:189–197.

    CAS  PubMed  Google Scholar 

  76. DiClemente N, Wilson C, Faure E, et al. Cloning, expression, and alternative splicing of the receptor for anit-Mullerian hormone. Mol Endocrinol 1994;8:1006–1020.

    Article  CAS  Google Scholar 

  77. Teixeira J, He WW, Shah PC, et al. Developmental expression of a candidate Mullerian inhibiting substance type II receptor. Endocrinology 1996;137:160–165.

    Article  CAS  PubMed  Google Scholar 

  78. Mishina Y, Tizard R, Deng JM, et al. Sequence, genomic organization and chromosomal location of the mouse Mullerian inhibiting substance type II receptor gene. Biochem Res Commun 1997;237:741–746.

    Article  CAS  Google Scholar 

  79. Tsuji M, Shima H, Yonemura CY, Brody J, Donahoe PK, Cunha GR. Effect of human recombinant Mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat. Endocrinology 1992;131:1481–1488.

    Article  CAS  PubMed  Google Scholar 

  80. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe, PK. Endometrial cancer is a receptor mediated target for Mullerian inhibiting substance. Proc Natl Acad Sci USA 2006;102:111–116. Erratum in: Proc Natl Acad Sci USA 2005;102:6513.

    Article  CAS  Google Scholar 

  81. Hoshiya Y, Gupta V, Segev DL, et al. Mullerian inhibiting substance induces NF kappa B signaling in breast and prostate cancer cells. Mol Cell Endocrinol 2003;211:43–49.

    Article  CAS  PubMed  Google Scholar 

  82. Gupta V, Carey JL, Kawakubo H, Muzikansky A, et al. Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci USA 2005; 102:3219–3224.

    Article  CAS  PubMed  Google Scholar 

  83. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA 2003; 100:15,601–15,906.

    Article  CAS  PubMed  Google Scholar 

  84. Josso N, Belville C, di Clemente N, Picard YP. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum Reprod Update. 2005;11:351–356. Review.

    Article  CAS  PubMed  Google Scholar 

  85. Gouedard L, Chen YG, Thevenet L, et al. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. J Biol Chem 2000;275: 27,973–27,978.

    CAS  PubMed  Google Scholar 

  86. Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Inraham HA. The serine/threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling. Mol Endocrinol 2001;15:936–945.

    Article  CAS  PubMed  Google Scholar 

  87. Jamin S, Arango NA, Mishina Y, Hanks MC, Behringer RR. Requirement of BMPR1a for Mullerian duct Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK. Müllerian inhibiting substance signaling uses a BMP-like pathway mediated by ALK2 and induces Smad6 expression. Mol Endocrinol 2001;15:946–995.

    Article  Google Scholar 

  88. He WW, Gustafson ML, Hirobe S, Donahoe PK. The developmental expression of four novel serine/threonine kinase receptors homologous to the activin/TGF-b II receptor family. Dev Dynamics 1993; 196:133–142.

    CAS  Google Scholar 

  89. Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK. Müllerian inhibiting substance Signaling uses a BMP-like pathway mediated by ALK2 and induces Smad6 expression. Mol Endocrinol 2001;15:946–959.

    Article  CAS  PubMed  Google Scholar 

  90. Gu Z, Reynolds EM, Song J, Lei H, Donahoe PK, Li E. The type I serine-threonine kinase receptor ActRIA functions in extraembryonic cells to regulate mouse gastrulation. Development 1999;126: 2551–2561.

    CAS  PubMed  Google Scholar 

  91. Lee MM, Donahoe PK, Silverman BL, et al. Mullerian inhibiting substance in the evaluation of children with nonpalpable gonads. New Engl J Med 1997;336:1480–1486.

    Article  CAS  PubMed  Google Scholar 

  92. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468–471.

    Article  PubMed  Google Scholar 

  93. van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065–3071.

    Article  PubMed  Google Scholar 

  94. Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? Brit J Obstet Gynaecol 2004;111:1248–1253.

    CAS  Google Scholar 

  95. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Barcie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 2004;82:1323–1329.

    Article  CAS  PubMed  Google Scholar 

  96. Penarrubia J, Fabregues F, Manau D, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist — gonadotropin treatment. Hum Reprod 2005;20:915–922.

    Article  CAS  PubMed  Google Scholar 

  97. Eldar-Geva T, Ben-Chetrit A, Spitz IM, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 2005;20:3178–3183.

    Article  CAS  PubMed  Google Scholar 

  98. Silberstein T, MacLaughlin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod 2006;21:159–163.

    Article  CAS  PubMed  Google Scholar 

  99. Gustafson ML, Lee MM, Scully RE, et al. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. New Engl J Med 1992;326:466–471.

    Article  CAS  PubMed  Google Scholar 

  100. Gustafson ML, Lee MM, Asmundson L, MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities. J Pedi Surg 1993; 28:439–444.

    Article  CAS  Google Scholar 

  101. Dutertre M, Gouedard L, Xavier F, et al. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology 2001;142:4040–4046.

    Article  CAS  PubMed  Google Scholar 

  102. Donahoe PK, Swann DA, Hayashi A, Sullivan MD. Müllerian duct regression in the embryo is correlated with cytotoxic activity against a human ovarian cancer. Science 1979;205:913–915.

    Article  CAS  PubMed  Google Scholar 

  103. Masiakos PT, MacLaughlin DT, Maheswaran S, et al. Human ovarian cancer, cell lines and primary ascites cells express the human MIS type II receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:488–499.

    Google Scholar 

  104. Price JM, Donahoe PK, Ito Y. Involution of the female Müllerian duct of the fetal rat in the organ culture assay for the detection of Müllerian inhibiting substance. Am J Anat 1979;156:265–284.

    Article  CAS  PubMed  Google Scholar 

  105. Price JM, Donahoe PK, Ito Y, Hendren WH. Programmed cell death in the Müllerian duct induced by Müllerian inhibiting substance. Am J Anat 1977;149:353–375.

    Article  CAS  PubMed  Google Scholar 

  106. Trelstad RL, Hayashi A, Hayashi K, Donahoe PK. The epithelial-mesenchymal interface of the male rat Mullerian duct: loss of basement membrane integrity and ductal regression. Dev Biol 1982;92:27–40.

    Article  CAS  PubMed  Google Scholar 

  107. Hayashi A, Donahoe PK, Budzik GP, Trelstad RL. Periductal and matrix glycosaminoglycans in rat Mullerian duct development and regression. Develop Biol 1982;92:16–26.

    Article  CAS  PubMed  Google Scholar 

  108. Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J Reprod Med 2005;50:426–438.

    PubMed  Google Scholar 

  109. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer Statistics. J Clin Cancer 2003; 53:5–26.

    Article  Google Scholar 

  110. Fuller AF Jr, Guy SR, Budzik GP, Donahoe PK. Müllerian inhibiting substance inhibits colony growth of a human ovarian cancer cell line. J Clin Endocrinol Metab 1982;54:1051–1055.

    Article  CAS  PubMed  Google Scholar 

  111. Donahoe PK, Fuller AF Jr, Scully RE, Guy SR, Budzik GP. Müllerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice. Ann Surg 1981;194:472–480.

    Article  CAS  PubMed  Google Scholar 

  112. Fuller AF, Jr, Krane IM, Budzik GP, Donahoe PK. Müllerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol Oncol 1985;22:135–148.

    Article  CAS  PubMed  Google Scholar 

  113. Chin T, Parry RL, Donahoe PK. Human Müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res 1991;51:2101–2106.

    CAS  PubMed  Google Scholar 

  114. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Highly purified Mullerian inhibiting substance inhibits ovarian cancer in vivo. Clin Cancer Res 2002;8:2640–2646.

    CAS  PubMed  Google Scholar 

  115. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA 2003; 100:15,601–15,606.

    Article  CAS  PubMed  Google Scholar 

  116. Connolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the Simian Virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63:1389–1397.

    CAS  PubMed  Google Scholar 

  117. Pieretti-Vanmarcke R, Donahoe PK, Szotek P, et al. Recombinant human Mullerian inhibiting substance inhibits long term growth of MISRII-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res 2006;12:1593–1598.

    Article  CAS  PubMed  Google Scholar 

  118. Segev DL, Hoshiya Y, Stephen AE, et al. Müllerian inhibiting substance regulates NFκB signaling and growth of mammary epithelial cells in vivo. J Biol Chem 2001;276:26,799–26,806.

    Article  CAS  PubMed  Google Scholar 

  119. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-κB/Rel Expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952–2960.

    Article  CAS  PubMed  Google Scholar 

  120. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629–3639.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Surgical Research Laboratory, Massachusetts General Hospital, Boston, MA, USA

    David T. MacLaughlin PhD & Patricia K. Donahoe PhD

Authors
  1. David T. MacLaughlin PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia K. Donahoe PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

MacLaughlin, D.T., Donahoe, P.K. (2008). Mullerian Inhibiting Substance: A Potential Nontoxic, Naturally Occurring Therapeutic Agent for Certain Human Cancers. In: Transforming Growth Factor-β in Cancer Therapy, Volume I. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-292-2_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-292-2_21

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-714-3

  • Online ISBN: 978-1-59745-292-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation